Dosimetric Analysis of a Phase I Study of PSMA-Targeting Radiopharmaceutical Therapy With [<sup>177</sup>Lu]Ludotadipep in Patients With Metastatic Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Dosimetric Analysis of a Phase I Study of PSMA-Targeting Radiopharmaceutical Therapy With [¹⁷⁷Lu]Ludotadipep in Patients With Metastatic Castration-Resistant Prostate Cancer

Published:2024 Issue:2 Volume:25 Page:179
ISSN:1229-6929
Container-title:Korean Journal of Radiology
language:en
Short-container-title:Korean J Radiol

Author:

Ha Seunggyun¹^ORCID,O Joo Hyun¹^ORCID,Park Chansoo²^ORCID,Boo Sun Ha¹^ORCID,Yoo Ie Ryung¹^ORCID,Moon Hyong Woo³^ORCID,Chi Dae Yoon²^ORCID,Lee Ji Youl³^ORCID

Affiliation:

1. Division of Nuclear Medicine, Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

2. Research Institute of Labeling, FutureChem Co., Ltd., Seoul, Republic of Korea.

3. Department of Urology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Funder

National Research Foundation of Korea

Publisher

XMLink

Link

https://kjronline.org/pdf/10.3348/kjr.2023.0656

Reference38 articles.

1. More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond

2. Current use of PSMA–PET in prostate cancer management

3. Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer

4. Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of novel PSMA-targeting [177Lu]Lu-P17-087 with its albumin binding derivative [177Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study;European Journal of Nuclear Medicine and Molecular Imaging;2024-04-25